<PlanDefinition xmlns="http://hl7.org/fhir"><id value="KDN5" /><meta><versionId value="1.9" /><lastUpdated value="2017-03-22T15:16:28.907+00:00" /><profile value="http://nccn.org/fhir/StructureDefinition/order-template" /></meta><text><status value="additional" /><div xmlns="http://www.w3.org/1999/xhtml">
  <div id="export-template-container">
    <table style="border-collapse: collapse; font-family: Arial; width: 100%; border-top: none 0px; border-bottom: solid 1px black;">
      <tr style="">
        <td style="width: 250px; vertical-align: top;">
          <img src="https://cott.ibmjstart.net/content/export/template-logo.png" alt="National Comprehensive Cancer Network" style="display: block; margin: 4px 4px;" />
        </td>
        <td style="vertical-align: top; padding: 0 0; padding-bottom: 5px; padding-left: 40px; width: 100%; max-width: 720px; overflow: hidden;">
          <div style="display: block; width: 100%;" id="header">
            <span style="display: block; width: 100%; font-size: 18px; margin-bottom: 5px" id="export-page-title">Chemotherapy Order Template</span>
            <span style="display: block; width: 100%; font-size: 21px; font-weight: bold; margin-bottom: 5px" id="export-disease-title">Kidney Cancer</span>
            <span style="display: block; width: 100%; font-size: 19px; font-weight: bold; margin-bottom: 5px; word-wrap: break-word" id="export-regimen-title">Gemcitabine/CARBOplatin</span>
            <div style="height: 5px; display: block; clear: both"></div>
          </div>
        </td>
        <td style="vertical-align: top; height: 100%;">
          <span style="text-align: right; display: block; width: 100%; vertical-align: top; float: right" id="export-template-id">
            <b>KDN5</b>
          </span>
        </td>
      </tr>
    </table>
    <div>
      <table id="export-template-info-section">
        <tr>
          <td id="export-template-indication">
            <h4>INDICATION:</h4>
            <span>Metastatic or Relapsed: Collecting duct/medullary subtypes</span>
          </td>
          <td id="export-template-references">
            <h4>REFERENCES:</h4>
            <ol>
              <li>
                <a href="http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf">NCCN Guidelines<sup>®</sup> for Kidney Cancer V.2.2017.</a>
              </li>
              <li>
                <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22The+Journal+of+urology%22%5BJour%5D+AND+1698%5Bpage%5D+AND+2007%5Bpdat%5D+AND+Oudard+S%5Bauthor%5D&amp;cmd=detailssearch">Oudard S et al. <em>J Urol</em>. 2007;177(5):1698-702.</a>
                <sup>
                  <a href="http://www.nccn.org/OrderTemplates/PDF/Appendix_E.pdf" title="NCCN references the regimen, and the template is consistent with the NCCN reference">a</a>
                </sup>
              </li>
            </ol>
          </td>
          <td id="export-template-emetic-risks">
            <h4>NCCN SUPPORTIVE CARE:</h4>
            <ol>
              <li>
                <i>Emetic risk:</i>
                <div style="display: inline-block"> Day 1 High; Day 8 Low</div>
              </li>
              <li>
                <i>Febrile Neutropenia Risk:</i>
                <span> Refer to <a href="http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf">NCCN Guidelines for Myeloid Growth Factors</a></span>
              </li>
            </ol>
          </td>
        </tr>
      </table>
    </div>
    <div style="clear: both;"></div>
    <div id="export-template-regimens">
      <div>
        <h4>
          <span>C</span>hemotherapy <span>R</span>egimen</h4>
        <i>21-day cycle for 6 cycles</i>
        <ul>
          <li>
            <b>Gemcitabine</b>
            <span>1250 mg/m<sup>2</sup> IV over 30 minutes on Days 1 and 8</span>
          </li>
          <li>
            <b>CARBOplatin</b>
            <span>AUC 5 IV over 30 minutes on Day 1</span>
            <ul>
              <li>See <em>Safety Parameters and Special Instructions</em> for information on AUC calculation.</li>
            </ul>
          </li>
        </ul>
      </div>
    </div>
    <div id="export-template-notes">
      <div>
        <h4>
          <span>S</span>upportive <span>C</span>are</h4>
        <h5>Antiemetic Therapy</h5>
        <div id="export-section-antiemetic-therapy">
          <ul>
            <li>Scheduled prophylactic antiemetic therapy should be given for prevention of acute and delayed nausea and vomiting based on the emetic risk of the chemotherapy regimen. This may include antiemetic therapy given on the days following chemotherapy. For more information on emetic prophylaxis, refer to the <a href="https://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf">NCCN Guidelines for Antiemesis</a> and <a href="https://www.nccn.org/OrderTemplates/PDF/appendix_D.pdf">Appendix D</a> to the NCCN Chemotherapy Order Templates.</li>
            <li>
              <strong>PRN for breakthrough:</strong> All patients should be provided with at least one medication for breakthrough emesis. Please consult the <a href="https://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf">NCCN Guidelines for Antiemesis</a> for appropriate antiemetic therapy.</li>
          </ul>
        </div>
        <h4>
          <span>M</span>onitoring and <span>H</span>old <span>P</span>arameters</h4>
        <div id="export-section-monitoring-and-hold-parameters">
          <ul>
            <li>CBC with differential should be monitored as clinically indicated for potential dose modification.</li>
            <li>
                    For gemcitabine:
                    <ul><li>Liver function should be monitored as clinically indicated for potential dose modification or discontinuation.</li><li><p>Renal function should be monitored as clinically indicated for potential dose modification or discontinuation.</p></li></ul></li>
            <li>
                    For CARBOplatin:
                    <ul><li><p>Hypersensitivity reaction may occur with cumulative infusions. Monitor for and treat hypersensitivity reactions per institutional standard. Based on severity of reaction, adjustment of premedications and infusion rates, implementation of a desensitization protocol or referral to a specialist, or discontinuation of therapy may be warranted. Refer to the "Management of Drug Reactions" algorithm in the <a href="http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf">NCCN Guidelines for Ovarian Cancer</a> for additional information and recommendations.</p></li><li>Renal function should be monitored prior to each cycle for potential dose modification or discontinuation.</li><li><p>Signs and symptoms of neurotoxicity should be monitored as clinically indicated for potential dose modification or discontinuation.</p></li></ul></li>
          </ul>
        </div>
        <h4>
          <span>S</span>afety <span>P</span>arameters and <span>S</span>pecial <span>I</span>nstructions</h4>
        <div id="export-safety-parameters">
          <ul>
            <li>
                    For CARBOplatin:
                    <ul><li><p>This agent is an irritant.</p></li><li>The FDA has recommended a maximum creatinine clearance for use in calculating CARBOplatin doses to minimize toxicity. The maximum dose is based on a GFR estimate that is capped at 125 mL/min for patients with normal renal function. Refer to <a href="http://www.nccn.org/OrderTemplates/PDF/appendix_B.pdf">Appendix B</a> for Calvert equation of AUC dose and Maximum CARBOplatin Dose calculation.</li></ul></li>
          </ul>
        </div>
      </div>
    </div>
    <div id="export-footer">
      <div></div>
    </div>
  </div>
  <div>
    <p>NCCN Chemotherapy Order Templates (NCCN Templates®) are peer-reviewed statements of the consensus of its authors derived from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) regarding their views of currently accepted approaches to treatment.
                        <em>An NCCN Template does not constitute an order</em>. Any clinician seeking to treat a patient using the NCCN Templates® is expected to use independent medical judgment in the context of individual clinical circumstances of a specific patient’s care or treatment. NCCN disclaims all warranties, express or implied including, without limitation, the implied warranties of merchantability and fitness for a particular purpose. NCCN does not warrant the accuracy, currency, or completeness of the NCCN Templates or make any representation regarding the use or the results of the use of the NCCN Templates in treatment. In no event shall NCCN or its members be liable for any damages including, without limitation, incidental, indirect, special, punitive, or consequential damages arising out of or in connection with the use of the NCCN Templates including, without limitation, loss of life, loss of data, loss of income or profit, losses sustained as a result of any injury to any person, or loss or damage to property or claims of third parties.</p>
    <p>National Comprehensive Cancer Network, Inc. ©2017. All rights reserved.</p>
  </div>
</div></text><contained><ActivityDefinition><id value="33361-1" /><meta><profile value="http://nccn.org/fhir/StructureDefinition/regimen-entry-template" /></meta><status value="active" /><kind value="MedicationRequest" /><productCodeableConcept><coding><system value="http://www.nlm.nih.gov/research/umls/rxnorm" /><code value="236234" /><display value="Gemcitabine hydrochloride" /></coding><text value="gemcitabine" /></productCodeableConcept><dosage><extension url="http://nccn.org/fhir/StructureDefinition/fullyStructured"><valueBoolean value="true" /></extension><text value="1250 mg/m2 IV over 30 minutes on Days 1 and 8" /><timing><extension url="http://nccn.org/fhir/StructureDefinition/daysOfCycle"><extension url="day"><valueInteger value="1" /></extension><extension url="day"><valueInteger value="8" /></extension></extension><repeat><duration value="30" /><durationUnit value="min" /></repeat></timing><route><coding><system value="http://snomed.info/sct" /><code value="47625008" /><display value="Intravenous route" /></coding><text value="IV" /></route><doseQuantity><value value="1250" /><unit value="mg/m²" /><system value="http://unitsofmeasure.org" /><code value="mg/m2" /></doseQuantity></dosage></ActivityDefinition></contained><contained><ActivityDefinition><id value="33360-1" /><meta><profile value="http://nccn.org/fhir/StructureDefinition/regimen-entry-template" /></meta><status value="active" /><kind value="MedicationRequest" /><productCodeableConcept><coding><system value="http://www.nlm.nih.gov/research/umls/rxnorm" /><code value="40048" /><display value="Carboplatin" /></coding><text value="CARBOplatin" /></productCodeableConcept><dosage><extension url="http://nccn.org/fhir/StructureDefinition/fullyStructured"><valueBoolean value="true" /></extension><text value="AUC 5 IV over 30 minutes on Day 1" /><timing><extension url="http://nccn.org/fhir/StructureDefinition/daysOfCycle"><extension url="day"><valueInteger value="1" /></extension></extension><repeat><duration value="30" /><durationUnit value="min" /></repeat></timing><route><coding><system value="http://snomed.info/sct" /><code value="47625008" /><display value="Intravenous route" /></coding><text value="IV" /></route><doseQuantity><value value="5" /><unit value="AUC" /><system value="http://snomed.info/sct" /><code value="413573002" /></doseQuantity></dosage></ActivityDefinition></contained><extension url="http://nccn.org/fhir/StructureDefinition/template-note"><extension url="id"><valueString value="mjm1mg" /></extension><extension url="section"><valueCode value="chemotherapyRegimen" /></extension><extension url="agentSubject"><valueCodeableConcept><coding><system value="http://www.nlm.nih.gov/research/umls/rxnorm" /><code value="40048" /><display value="carboplatin" /></coding></valueCodeableConcept></extension><extension url="content"><valueString value="See  Safety Parameters and Special Instructions  for information on AUC calculation." /></extension></extension><extension url="http://nccn.org/fhir/StructureDefinition/template-note"><extension url="id"><valueString value="mjywmq" /></extension><extension url="section"><valueCode value="monitoringAndHoldParameters" /></extension><extension url="content"><valueString value="CBC with differential should be monitored as clinically indicated for potential dose modification." /></extension></extension><extension url="http://nccn.org/fhir/StructureDefinition/template-note"><extension url="id"><valueString value="ndkzmq" /></extension><extension url="section"><valueCode value="monitoringAndHoldParameters" /></extension><extension url="agentSubject"><valueCodeableConcept><coding><system value="http://www.nlm.nih.gov/research/umls/rxnorm" /><code value="236234" /><display value="gemcitabine" /></coding></valueCodeableConcept></extension><extension url="content"><valueString value="Liver function should be monitored as clinically indicated for potential dose modification or discontinuation." /></extension></extension><extension url="http://nccn.org/fhir/StructureDefinition/template-note"><extension url="id"><valueString value="mji0nq" /></extension><extension url="section"><valueCode value="monitoringAndHoldParameters" /></extension><extension url="agentSubject"><valueCodeableConcept><coding><system value="http://www.nlm.nih.gov/research/umls/rxnorm" /><code value="236234" /><display value="gemcitabine" /></coding></valueCodeableConcept></extension><extension url="content"><valueString value="Renal function should be monitored as clinically indicated for potential dose modification or discontinuation." /></extension></extension><extension url="http://nccn.org/fhir/StructureDefinition/template-note"><extension url="id"><valueString value="mjaz" /></extension><extension url="section"><valueCode value="monitoringAndHoldParameters" /></extension><extension url="agentSubject"><valueCodeableConcept><coding><system value="http://www.nlm.nih.gov/research/umls/rxnorm" /><code value="40048" /><display value="carboplatin" /></coding></valueCodeableConcept></extension><extension url="content"><valueString value="Hypersensitivity reaction may occur with cumulative infusions. Monitor for and treat hypersensitivity reactions per institutional standard. Based on severity of reaction, adjustment of premedications and infusion rates, implementation of a desensitization protocol or referral to a specialist, or discontinuation of therapy may be warranted. Refer to the &quot;Management of Drug Reactions&quot; algorithm in the  NCCN Guidelines for Ovarian Cancer for additional information and recommendations." /></extension></extension><extension url="http://nccn.org/fhir/StructureDefinition/template-note"><extension url="id"><valueString value="mja0" /></extension><extension url="section"><valueCode value="monitoringAndHoldParameters" /></extension><extension url="agentSubject"><valueCodeableConcept><coding><system value="http://www.nlm.nih.gov/research/umls/rxnorm" /><code value="40048" /><display value="carboplatin" /></coding></valueCodeableConcept></extension><extension url="content"><valueString value="Renal function should be monitored prior to each cycle for potential dose modification or discontinuation." /></extension></extension><extension url="http://nccn.org/fhir/StructureDefinition/template-note"><extension url="id"><valueString value="ntazna" /></extension><extension url="section"><valueCode value="monitoringAndHoldParameters" /></extension><extension url="agentSubject"><valueCodeableConcept><coding><system value="http://www.nlm.nih.gov/research/umls/rxnorm" /><code value="40048" /><display value="carboplatin" /></coding></valueCodeableConcept></extension><extension url="content"><valueString value="Signs and symptoms of neurotoxicity should be monitored as clinically indicated for potential dose modification or discontinuation." /></extension></extension><extension url="http://nccn.org/fhir/StructureDefinition/template-note"><extension url="id"><valueString value="mtcx" /></extension><extension url="section"><valueCode value="safetyParametersAndSpecialInstructions" /></extension><extension url="agentSubject"><valueCodeableConcept><coding><system value="http://www.nlm.nih.gov/research/umls/rxnorm" /><code value="40048" /><display value="carboplatin" /></coding></valueCodeableConcept></extension><extension url="content"><valueString value="This agent is an irritant." /></extension></extension><extension url="http://nccn.org/fhir/StructureDefinition/template-note"><extension url="id"><valueString value="mja4" /></extension><extension url="section"><valueCode value="safetyParametersAndSpecialInstructions" /></extension><extension url="agentSubject"><valueCodeableConcept><coding><system value="http://www.nlm.nih.gov/research/umls/rxnorm" /><code value="40048" /><display value="carboplatin" /></coding></valueCodeableConcept></extension><extension url="content"><valueString value="The FDA has recommended a maximum creatinine clearance for use in calculating CARBOplatin doses to minimize toxicity. The maximum dose is based on a GFR estimate that is capped at 125 mL/min for patients with normal renal function. Refer to Appendix B for Calvert equation of AUC dose and Maximum CARBOplatin Dose calculation." /></extension></extension><extension url="http://nccn.org/fhir/StructureDefinition/template-note"><extension url="id"><valueString value="mzaznq" /></extension><extension url="section"><valueCode value="supportiveCareAntiemeticTherapy" /></extension><extension url="content"><valueString value="Scheduled prophylactic antiemetic therapy should be given for prevention of acute and delayed nausea and vomiting based on the emetic risk of the chemotherapy regimen. This may include antiemetic therapy given on the days following chemotherapy. For more information on emetic prophylaxis, refer to the  NCCN Guidelines for Antiemesis and Appendix D to the NCCN Chemotherapy Order Templates." /></extension></extension><extension url="http://nccn.org/fhir/StructureDefinition/template-note"><extension url="id"><valueString value="mzaynw" /></extension><extension url="section"><valueCode value="supportiveCareAntiemeticTherapy" /></extension><extension url="content"><valueString value="PRN for breakthrough: All patients should be provided with at least one medication for breakthrough emesis. Please consult the NCCN Guidelines for Antiemesis for appropriate antiemetic therapy." /></extension></extension><identifier><system value="http://nccn.org/ordertemplates/ID" /><value value="KDN5" /></identifier><version value="1" /><title value="Gemcitabine/CARBOplatin" /><type><coding><system value="http://hl7.org/fhir/plan-definition-type" /><code value="protocol" /><display value="Protocol" /></coding><text value="Chemotherapy Order Template" /></type><status value="active" /><experimental value="true" /><date value="2017-03-22" /><publisher value="National Comprehensive Cancer Network, Inc." /><useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"><valueString value="metastatic: collecting duct/medullary subtypes" /></extension><code><system value="http://hl7.org/fhir/usage-context-type" /><code value="focus" /></code><valueCodeableConcept><text value="Kidney Cancer" /></valueCodeableConcept></useContext><useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"><valueString value="metastatic: collecting duct/medullary subtypes" /></extension><code><system value="http://nccn.org/fhir/CodeSystem/indication-classes" /><code value="treatmentSetting" /></code><valueCodeableConcept><text value="metastatic" /></valueCodeableConcept></useContext><useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"><valueString value="metastatic: collecting duct/medullary subtypes" /></extension><code><system value="http://nccn.org/fhir/CodeSystem/indication-classes" /><code value="disease-or-histology" /></code><valueCodeableConcept><text value="collecting duct/medullary subtypes" /></valueCodeableConcept></useContext><useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"><valueString value="relapsed: collecting duct/medullary subtypes" /></extension><code><system value="http://hl7.org/fhir/usage-context-type" /><code value="focus" /></code><valueCodeableConcept><text value="Kidney Cancer" /></valueCodeableConcept></useContext><useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"><valueString value="relapsed: collecting duct/medullary subtypes" /></extension><code><system value="http://nccn.org/fhir/CodeSystem/indication-classes" /><code value="treatmentSetting" /></code><valueCodeableConcept><text value="relapsed" /></valueCodeableConcept></useContext><useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"><valueString value="relapsed: collecting duct/medullary subtypes" /></extension><code><system value="http://nccn.org/fhir/CodeSystem/indication-classes" /><code value="disease-or-histology" /></code><valueCodeableConcept><text value="collecting duct/medullary subtypes" /></valueCodeableConcept></useContext><contributor><type value="author" /><name value="Evelyn Handel" /></contributor><contributor><type value="author" /><name value="Mary Visceglia" /></contributor><contributor><type value="author" /><name value="Sarah DeVincenzo" /></contributor><copyright value="All rights reserved." /><relatedArtifact><type value="derived-from" /><display value="NCCN Guidelines® for Kidney Cancer V.2.2017." /><url value="http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf" /></relatedArtifact><relatedArtifact><type value="citation" /><display value="Oudard S et al. J Urol. 2007;177(5):1698-702." /><url value="http://www.ncbi.nlm.nih.gov/pubmed?term=%22The+Journal+of+urology%22%5BJour%5D+AND+1698%5Bpage%5D+AND+2007%5Bpdat%5D+AND+Oudard+S%5Bauthor%5D&amp;cmd=detailssearch" /></relatedArtifact><action><extension url="http://nccn.org/fhir/StructureDefinition/febrileNeutropeniaRisk"><valueCode value="referToMgf" /></extension><action><code><text value="regimen option" /></code><action id="regimenPart-1fa98ee5-0fbc-48b9-92e4-b822f2121e16"><extension url="http://nccn.org/fhir/StructureDefinition/emeticRisk"><extension url="http://nccn.org/fhir/StructureDefinition/fullyStructured"><valueBoolean value="true" /></extension><extension url="schedule"><valueTiming><extension url="daysOfCycle"><extension url="day"><valueInteger value="1" /></extension></extension></valueTiming></extension><extension url="level"><valueCode value="high" /></extension></extension><extension url="http://nccn.org/fhir/StructureDefinition/emeticRisk"><extension url="http://nccn.org/fhir/StructureDefinition/fullyStructured"><valueBoolean value="true" /></extension><extension url="schedule"><valueTiming><extension url="daysOfCycle"><extension url="day"><valueInteger value="8" /></extension></extension></valueTiming></extension><extension url="level"><valueCode value="low" /></extension></extension><code><text value="regimen part" /></code><selectionBehavior value="exactly-one" /><action id="cycle-c4facaba-52f6-43d6-bf59-69158ae3c9fa"><extension url="http://nccn.org/fhir/StructureDefinition/fullyStructured"><valueBoolean value="true" /></extension><textEquivalent value="21-day cycle for 6 cycles" /><code><text value="cycle definition" /></code><timingTiming><repeat><extension url="http://nccn.org/fhir/StructureDefinition/countUnits"><valueCode value="cycles" /></extension><count value="6" /><duration value="21" /><durationUnit value="d" /></repeat></timingTiming><action id="regimenEntryGroup-16895-32133"><code><text value="regimen entry group" /></code><selectionBehavior value="exactly-one" /><action id="regimenEntry-16895-32133"><code><text value="regimen entry" /></code><action id="gemcitabine-33361"><code><text value="dosage instruction group" /></code><selectionBehavior value="exactly-one" /><action id="gemcitabine-33361-1"><code><text value="dosage instruction" /></code><type><system value="http://hl7.org/fhir/action-type" /><code value="create" /></type><definition><reference value="#33361-1" /></definition></action></action></action></action><action id="regimenEntryGroup-16895-32132"><code><text value="regimen entry group" /></code><selectionBehavior value="exactly-one" /><action id="regimenEntry-16895-32132"><code><text value="regimen entry" /></code><action id="carboplatin-33360"><code><text value="dosage instruction group" /></code><selectionBehavior value="exactly-one" /><action id="carboplatin-33360-1"><code><text value="dosage instruction" /></code><type><system value="http://hl7.org/fhir/action-type" /><code value="create" /></type><definition><reference value="#33360-1" /></definition></action></action></action></action></action></action></action></action></PlanDefinition>